Dimensional Fund Advisors LP Boosts Holdings in Maravai LifeSciences Holdings, Inc. $MRVI

Key Points

• Dimensional Fund Advisors increased its Maravai LifeSciences stake by 64.8% in the first quarter, adding 558,050 shares and bringing its holdings to 1.42 million shares, worth about $4.0 million. Institutional investors collectively own 50.25% of the company.
• Maravai reported quarterly revenue of $51.44 million and an adjusted loss of $0.02 per share, beating analyst expectations for $48.67 million in revenue and a $0.04-per-share loss. The company remains unprofitable, with a negative net margin of 37.07%.
• Analyst views remain mixed: Wells Fargo raised its price target to $6.50 and Deutsche Bank maintained a buy rating, while UBS reiterated a reduce rating. The overall consensus is “Hold,” with a $6.25 target price.

Dimensional Fund Advisors LP boosted its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 64.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,418,597 shares of the company's stock after buying an additional 558,050 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.55% of Maravai LifeSciences worth $4,015,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in Maravai LifeSciences in the fourth quarter worth about $34,000. Insigneo Advisory Services LLC purchased a new position in shares of Maravai LifeSciences during the 4th quarter valued at about $34,000. Quantessence Capital LLC purchased a new position in shares of Maravai LifeSciences during the 3rd quarter valued at about $31,000. Stifel Financial Corp bought a new position in shares of Maravai LifeSciences during the 4th quarter valued at approximately $36,000. Finally, Jain Global LLC bought a new position in shares of Maravai LifeSciences during the 4th quarter valued at approximately $36,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the business's stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total value of $126,500.00. Following the sale, the general counsel owned 360,767 shares in the company, valued at $1,825,481.02. The trade was a 6.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is currently owned by insiders.

Maravai LifeSciences Trading Down 0.5%

Shares of MRVI opened at $5.78 on Thursday. The firm has a market cap of $1.49 billion, a P/E ratio of -11.12 and a beta of 0.63. The company has a debt-to-equity ratio of 0.72, a current ratio of 5.91 and a quick ratio of 4.96. Maravai LifeSciences Holdings, Inc. has a 1 year low of $2.28 and a 1 year high of $7.44. The company has a 50 day simple moving average of $6.05 and a two-hundred day simple moving average of $4.43.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $51.44 million for the quarter, compared to the consensus estimate of $48.67 million. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.34%. On average, equities analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Wells Fargo & Company raised their target price on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Wall Street Zen lowered shares of Maravai LifeSciences from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $6.00 price objective on shares of Maravai LifeSciences in a research note on Friday, May 8th. UBS Group restated a "reduce" rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Finally, Weiss Ratings upgraded shares of Maravai LifeSciences from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, May 29th. Two research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Maravai LifeSciences has a consensus rating of "Hold" and a consensus target price of $6.25.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source